# Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants

> **NCT05386810** · PHASE3 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 1572 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Experimental vaccine
- **BIOLOGICAL:** IPV control vaccine
- **BIOLOGICAL:** single-person sIPV control vaccine

## Key facts

- **NCT ID:** NCT05386810
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-05
- **Primary completion:** 2022-10-08
- **Final completion:** 2023-07-20
- **Target enrollment:** 1572 (ACTUAL)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386810, "Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05386810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*